



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone:91-11-26925858,26925801,Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>



Ref: IMCL/CS/BM/2024

5th August, 2024

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 5th August, 2024

Dear Sir,

This is to inform that the Board of Directors of the Company has, at its meeting held on Monday, 5th August, 2024 (i.e. today), inter-alia, considered and approved the following items:

- 1. The Un-audited Financial Results of the company for the quarter ended 30th June, 2024.**

Considered and approved the Un-audited Financial Results for the quarter ended 30th June, 2024, along with the Limited Review Report of the statutory auditors.

- 2. The re-appointment of Mr. Shivakumar Pattabhiraman (DIN: 08570283) as Managing Director**

Approved the re-appointment of Mr. Shivakumar Pattabhiraman (DIN: 08570283) as Managing Director, for a period of 2 years effective from 5th November, 2024 to 4th November, 2026, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company and such other approvals as may be necessary.

- 3. Convening Annual General Meeting**

Approved convening the thirty-sixth Annual General Meeting (AGM) of the Company, on Tuesday, 24th September, 2024, through video conferencing / other audio-visual means.



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi – 110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phone:91-11-26925858,26925801,Fax: 91-11-26823629

E-mail: imcl@apollohospitals.com, Website : <https://www.apollohospitals.com/delhi/>



4. Fixation of Record/Book Closure Dates

The Register of Members and Share Transfer Books of the Company shall remain closed from Saturday, 14th September, 2024 to Tuesday, 24th September, 2024 (both days inclusive) for the purpose of the AGM and declaration of dividend.

The Board meeting commenced at 3.30 p.m. and ended at 5.45 p.m.

We are enclosing herewith the Un-audited Financial Results for the quarter ended 30th June, 2024, along with a copy of the Limited Review Report by the Statutory Auditors of the Company, and the details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023, for the re-appointment of Mr. Shivakumar Pattabhiraman as managing Director of the Company.

This is for your information and record.

Thanking You,

Yours sincerely,

For Indraprastha Medical Corporation Limited

Priya Ranjan
AVP – Corporate Affairs & Legal
(Company Secretary & Compliance Officer)

Encl.: As above

Limited Review Report on Unaudited Quarterly Results

To the Board of Directors of Indraprastha Medical Corporation Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Indraprastha Medical Corporation Limited** ("the Company") for the quarter ended 30 June 2024 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder; and other accounting principles generally accepted in India. Our responsibility is to issue a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S.N. Dhawan & CO LLP**

Chartered Accountants

Firm Registration No.: 000050N/N500045



Bhaskar Sen

Partner

Membership No.: 096985

UDIN: 24096985BKBWGF751



Place: New Delhi

Date: 05 August 2024


Statement of Unaudited Financial Results for the Quarter ended 30th June, 2024

S. No.	Particulars	Amount (Rs. in crore)			
		Quarter ended			Year ended
		30.06.2024 (Unaudited)	31.03.2024 (Refer Note 3)	30.06.2023 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	347.86	314.73	306.51	1244.70
2	Other income	5.12	4.89	3.56	16.89
3	Total income	352.98	319.62	310.07	1261.59
4	Expenses				
	a) Cost of materials consumed	58.93	55.54	54.18	217.19
	b) Employee benefits expense	66.59	64.79	63.27	261.61
	c) Professional charges to doctors	90.67	80.12	77.03	311.79
	d) Finance costs	1.61	1.56	0.78	4.06
	e) Depreciation and amortisation expense	11.04	10.21	9.81	40.08
	f) Other expenses	64.55	65.84	64.77	260.75
	Total expenses	293.39	278.06	269.84	1095.48
5	Profit before exceptional items and tax	59.59	41.56	40.23	166.11
6	Exceptional items	-	-	-	-
7	Profit before tax (PBT)	59.59	41.56	40.23	166.11
8	Tax expense				
	Current tax	15.21	9.17	10.91	43.03
	Deferred tax	(0.39)	1.22	(1.18)	(0.88)
9	Profit for the period after tax (PAT)	44.77	31.17	30.50	123.96
10	Other comprehensive income				
	a) (i) Items that will not be reclassified to profit or loss	2.64	1.28	(0.46)	2.47
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.66)	(0.32)	0.12	(0.62)
	Total other comprehensive income (Net of tax expenses)	1.98	0.96	(0.34)	1.85
11	Total comprehensive income for the period	46.75	32.13	30.16	125.81
12	Paid-up equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year				386.09
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	4.88	3.40	3.33	13.52

Notes:

1. The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 5th August, 2024.
2. The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
3. The financial results for the three months ended 31st March, 2024 are the balancing figures between the audited figures for the year ended 31st March, 2024 and the unaudited year to date figures for the nine months ending 31st December, 2023, which were subject to limited review.
4. Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : New Delhi
Date : 5th August, 2024


Shivakumar Pattabhiraman
(Managing Director)
DIN: 08570283



Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023:

S. No.	Particulars	Mr. Shivakumar Pattabhiraman (DIN 08570283)
1	Reason for change (Re-Appointment)	Re-appointment as Managing Director of the Company, for a period of 2 years from 5 th November, 2024 to 4 th November, 2026, subject to the approval of the shareholders.
2	Date of Re-Appointment	Effective from 5 th November, 2024.
3	Term of Re-Appointment	For a period of 2 years starting from 5 th November, 2024 to 4 th November, 2026.
3	Brief Profile	<p>Mr. Shivakumar Pattabhiraman is an Associate Member of the Institute of Chartered Accountants of India (ICAI) and the Institute of Cost & Management Accountants of India. He has experience spanning over 33 years with 27 years in the healthcare domain.</p> <p>He started his career as a System Analyst and acquired practical skills in designing computer based applications for business / accounting solutions. He was instrumental in implementing computerized financial system at Croslands Research Laboratories, Mumbai. He headed the Resources Department in Times Guaranty Financials Ltd. (part of Bennett, Coleman & Co. Ltd.), Mumbai. He worked for Premier Auto Electric Ltd. at Chennai for a period of one year before joining Indraprastha Medical Corporation Ltd. (MCL) in April, 1997 as Dy. General Manager (Finance). He rose to the position of Chief Operating & Chief Financial Officer at IMCL.</p> <p>He moved to the Group Headquarters of Apollo Hospitals at Chennai in June, 2017., as Chief Executive Officer of Apollo Hospitals, Chennai Division. Initially, he was appointed as Managing Director of IMCL for a period of 2 years w.e.f. 5th November, 2019, then after re-appointed as Managing Director for a period of 3 years from 5th November, 2021. His present term is upto 4th November, 2024. He is not related to any other Director of the Company and is not debarred from holding office of a Director by virtue of any SEBI Order or any other such authority. He is not holding any shares in the share capital of the Company.</p>
4	Disclosure of relationships between the Directors	Mr. Shivakumar Pattabhiraman is not related to any Directors of the Company.

Shivakumar Pattabhiraman

